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Summary It has been proposed that the generation of 102 during photodynamic therapy (PDT) may lead to photochemical depletion of
ambient tumour oxygen, thus causing acute hypoxia and limiting treatment effectiveness. We have studied the effects of fluence rate on P02,
in the murine RIF tumour during and after PDT using 5 mg kg-' Photofrin and fluence rates of 30, 75 or 150 mW cm-2. Median P02 before PDT
ranged from 2.9 to 5.2 mmHg in three treatment groups. Within the first minute of illumination, median tumourP02 decreased with all fluence
rates to values between 0.7 and 1.1 mmHg. These effects were rapidly and completely reversible if illumination was interrupted. During
prolonged illumination (20-50 J cm-2) P02 recovered at the 30 mW cm-2fluence rate to a median value of 7.4 mmHg, but remained low atthe
150 mW cm-2 fluence rate (median P02 1.7 mmHg). Fluence rate effects were not found after PDT, and at both 30 and 150 mW cm-2 median
tumour P02 fell from control levels to 1.0-1.8 mmHg within 1-3 h after treatment conclusion. PDT with 100 J cm-2 at 30 mW cm-2 caused
significantly (P= 0.0004) longer median tumour regrowth times than PDT at 150 mW cm-2, indicating that lowerfluence rate can improve PDT
response. Vascular perfusion studies uncovered significant fluence rate-dependent differences in the responses of the normal and tumour
vasculature. These data establish a direct relationship between tumourP02, the fluence rate applied during PDT and treatment outcome. The
findings are of immediate clinical relevance.
Keywords: photodynamic therapy; fluence rate; tumour oxygenation; photochemical oxygen depletion; acute hypoxia; microvascular
perfusion
Photodynamic therapy (PDT) with Photofrin is arecently approved
modality for the treatment of cancer of the oesophagus, lung,
bladder, stomach andcervix in various countries andisbeing tested
clinically for the treatment ofother malignancies and some benign
conditions. In PDT, a tissue-localized photosensitizer is excited by
visible light in the red or near-infrared spectral region. Cellular
damage occurs when the photosensitizer in its excited triplet state
transfers its energy to ground-state molecular oxygen (302),
creating cytotoxic oxygen species, primarily singlet oxygen ('02)
(Henderson and Dougherty, 1992). It follows that 302 is essential
for PDT cytotoxicity. Indeed, it has been demonstrated in vitro and
in vivo that cell and/or tissue damage are absent when PDT is
given under anoxic conditions (Gomer and Razum, 1984; Moan
and Sommer, 1985; Henderson and Fingar, 1987). For in vivo PDT
effectiveness, tissuepO2 may therefore be a determining factor.
In tumours, pre-existing regional hypoxia has been recognized
as a barrier to effective treatment with other oxygen-dependent
modalities, such as radiotherapy, and it may play a role in PDT as
well (Fingar et al, 1992a). In addition, there exist two mechanisms
by which PDT itself may induce tissue hypoxia and thus become
self-limiting. Hypoxia may result from PDT-mediated damage to
the microvasculature, which usually develops with time after PDT,
but which can occur acutely during light delivery at high photo-
sensitizer and light doses with certain photosensitizers (Henderson
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and Fingar, 1989). The second mechanism that may lead to tissue
hypoxia is the consumption of3°2 in the PDT-mediated formation
and consumption of 102. Very rapid and substantial reductions in
tissue oxygen tensions upon illumination ofphotosensitized tissue
have been detected with transcutaneous oxygen electrodes by
Tromberg et al (1990). Mathematical modelling by Foster et al
(1991) has demonstrated that the rate of oxygen consumption
during Photofrin PDT may be significant enough to move a frac-
tion of the tumour into very low levels ofoxygenation, outpacing
the rate ofoxygen diffusion from the capillaries and shrinking the
radius ofoxygenated tissue volume around them.
The rate of '02 generation is influenced by the fluence rate of
illumination, suggesting that 302 consumption may in part be
controlledby this treatmentparameter. Studies in multicell tumour
spheroids in vitro have revealed a strong relationship between the
fluence rate, oxygen consumption (measured both by oxygen
microelectrodes and modelled mathematically) and the fraction of
PDT surviving cells (Foster et al, 1993; Nichols and Foster, 1994).
The superior effectiveness of lower fluence rates in delaying
tumour regrowth compared with treatments at higher fluence rates
with the same overall fluence has been demonstrated by Gibson et
al (1990) and Foster et al (1991). These results may be explained,
at least theoretically, by more sustained tumour oxygenation
throughout the course of treatment (Foster et al, 1991, 1993;
Nichols and Foster, 1994).
This paper provides an experimental analysis of the relation-
ships between fluence rate oflight treatment, tumour oxygenation,
vascular perfusion of tumour and normal skin, and tumour
response.
1386Tumouroxygenation duringphotodynamic therapy 1387
MATERIALS AND METHODS
Animals and tumour system
The RIF (radiation-induced fibrosarcoma) transplantable tumour,
propagated in 8- to 12-week-old female C3Hf/HeRos mice
(obtained from the RPCI breeding facilities), was used for all
experiments requiring tumours. All aspects of animal experimen-
tation and husbandry were carried out in compliance with federal
and state standards, and were approved by the Animal Care and
Use Committee of RPCI. For tumour inoculation, 3 x 105 RIF
cells, obtained from established tumours by enzyme digestion
according to established procedures of successive in vitro and in
vivo passage (Twentyman et al, 1980), were injected intradermally
on the animals' right shoulder, the inoculation site having been
shaved and depilated with Nair 24 h earlier. Animals were used
5-7 days after inoculation, when their tumours were about
4-6 mm in diameter and 2-4 mm in height. For microvascular
perfusion studies of the skin, an area (1 cm in diameter) was also
depilated on the left shoulder.
Photosensitizers
Photofrin (QLT PhotoTherapeutics, Vancouver, BC, Canada) was
used in all experiments. It was reconstituted in 5% dextrose in
water (D5W) according to company instructions. Mice were
injected i.v. (via tail vein) with 5 mg kg-' Photofrin 24 h before
light exposure.
Determination of photosensitizer tumour
concentrations
Tumour concentrations of Photofrin were determined 24 h after
photosensitizer administration by fluorescence measurements
after tissue solubilization as described (Bellnier et al, 1997).
Fluorescence spectra of test samples were compared with a stan-
dard curve and gg of drug per g of tumour was calculated. The
obtained values were used as input parameters for the computer
simulation of302 and 1O2distlibutions (see below).
In vivo photodynamic treatment
Twenty-four hours after photosensitizer administration, tumours
and/or normal skin were exposed to light from a dye laser (Model
375, Spectra-Physics, Mountain View, CA, USA) pumped by an
argon-ion laser (either Trimedyne Optilase, Santa Anna, CA,
USA, or Model 171, Spectra-Physics). The dye laser was coupled
to a 200-gm diameter quartz fibre fitted with a GRIN lens to
provide uniform illumination. The light was set at a wavelength of
630 nm with a monochromator (DMC1-02, Optometrics USA,
Ayer, MA, USA). Power output was measured with a thermal disc
calorimeter (Model 210, Coherent, Auburn, CA, USA), and the
power density was adjusted over a treatment field of 1 cm in diam-
eter to yield fluence rates of 30, 75 or 150 mW cm-2. Total treat-
ment fluences varied with the experimental end point to be
measured and are given under Results.
Measurement of tumour P02
Intratumour pO2 was measured polarographically using the
Eppendorf pO2 Histograph (Eppendorf Scientific, Madison, WI,
USA) (Vaupel et al, 1991). Before andbetween measurements, the
instrument was calibrated in 0.9% saline bubbled alternately with
air and nitrogen to set 100% and 0% pO2 currents. Ambient air
pressure and tumour temperature (measured using an Omega 30
gauge, '/2-inch needle thermocouple) were recorded and used to
post-calibrate the data. For each experimental condition, the last
track used for pO2 measurement was used for insertion of the
thermocouple.
Tumours ranging in size from 45 to 145 mm3 were used for
oxygen measurements; at that size, no spontaneous tumour
necrosis is evident. Measurements were performed under sodium
pentobarbital anaesthesia (66 mg kg-' i.p.) unless otherwise
indicated. The 300-gm-diameter polarographic needle probe was
aligned at the tumour surface after creation of a pinpoint hole,
using a hypodermic needle, in the skin covering the tumour. The
probe was advanced one step to ensure the tip was within the
tumour, and automatic probe advancement was begun after the
p02 values had stabilized. Probe advancement was set to a0.7-mm
forward step and a 0.3-mm retraction step for each reading. Probe
track length and number of tracks measured were determined by
tumour dimensions. Tracking was horizontal through the tumour,
and care was taken to choose comparable track positions (tumour
periphery vs centre) for control and experimental measurements.
One to two tracks were measured for each measurement condition
(see below), with a maximum ofsix tracks per tumour.
PDT treatments were carried out at fluence rates of 30, 75 or
150 mW cm-2. The following measurement protocols were used:
(1) in each tumour, pO2 was measured immediately before illumi-
nation, within the first minute into illumination, and again
during illumination when similar total light fluences in the range
of 20-50 J cm-2 were reached; for measurements within the first
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Figure 1 Simulated fluence rate-dependent PDT effects on RIF tumour
oxygenation, plotted with PDT MODeM as a function of radial distance from a
capillary. (A) 302 distribution in FM. (B) 102 distribution in pM. *, Metabolic
3°2 consumption without PDT; PDT at 30 (A), 75 (0) or 150 mW cm-2 (K)
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minute the probe was aligned before illumination, while for
measurements at the longer time intervals the probe was aligned
during illumination; the fluence range of 20-50 J cm-2 was
dictated by the time required to align the probe and carry out the
PO2 measurements, i.e. measurements at 150 mW cm-2 were
carried out between 2 and 6min into illumination, whereas
measurements at 30 mW cm-2 were carried out between 20 and
26 min into illumination; (2) in each tumour, P02 was measured
within the first minute of illumination, the light was removed and
pO2 was again measured within the first minute after illumination;
(3) in separate groups oftumours, pO2 was measured immediately
and at 1, 3 and 5 h after a full treatment dose (100 J cm-2) ofPDT.
Appropriate control measurements were also performed on totally
untreated tumours and tumours receiving light only, as well as on
untreated tumours in mice with or without anaesthesia. In experi-
ments that required prolonged illumination, mice were kept warm
using a microwaveable hot pad. Five to ten animals were used per
experimental group. Data are expressed as mean and median
values, as well as percentages ofvalues < 2 mmHg and .5 mmHg.
These parameters were chosen for analysis because they lie within
the range of oxygen concentrations reported in the literature, in
which 102 formation becomes limited by oxygen availability
(Moan and Sommer, 1985; Foster and Nichols, 1995).
Determination of tumour response
The animals were restrained, unanaesthetized, in specially
designed holders and PDT was carried out at fluence rates
of 30, 75 and 150 mW cm-2, with a total fluence of 75, 100 and
135 J cm-2 being delivered at each fluence rate. After treatment,
tumour size was recorded 6 days a week for 30 days, and then
weekly up to 90 days. Tumour size was measured intwo orthogonal
dimensions using an electronic calliper (Ultra-Cal Mark III, FredV
Fowler, Newton, MA, USA) and automatically entered into a
spreadsheet (Excel, Microsoft, Redmond, WA, USA). Tumour
volume was calculated with the formula V= (1 x w2)/2, and time to
reach 400 mm3 was estimated using the natural log ofthe volume.
Groups of eight to thirteen animals were evaluated. Results are
presented as Kaplan-Meier curves in which the percentage of
animals with tumour volumes less than 400 mm3 is plotted against
the number of hours since treatment (GraphPad Prism, GraphPad
Software, San Diego, CA, USA).
Fluorescein exclusion assay of skin microvascular
perfusion
This method for assessing microvascular perfusion of the normal
skin before and after PDT has been described in detail earlier
(Bellnier et al, 1995). Briefly, immediately after PDT light expo-
sure and at 1, 3, 5 and 24 h thereafter, unanaesthetized animals
were injected with 0.2 ml of 2 mg ml-' fluorescein (JT Baker
Chemical, Phillipsburg, NJ, USA) in Hanks' balanced salt solution
(HBSS) via the orbital plexus. Five to 8 min after fluorescein
injection, fluorescein-specific fluorescence within and outside the
treatment field (four readings each) was detected by a fluorometer.
At least three mice were evaluated for each data point. Data were
recorded as the ratio (treated/untreated sites) ofthe mean values of
the measurements. The PDT treatment parameters for these exper-
iments were a total fluence of 100 J cm-2 at fluence rates of30, 75
and I00 mWcm-2.
'*RbCI uptake as a measure of tumour and skin
microvascular perfusion
This technique has been described by others (Lyng et al, 1992) and
was used with slight modifications. Briefly, 86RbCl in 0.5 M
Table 1 Effects of fluence rate on tumourP02 during Photofrin PDTa
Treatment No. Mean tumour No. Mean P02 Median P02 % of values % of values
condition of volume of (mmHg) (mmHg) < 2 mmHg .5 mmHg
mice (mm3 + s.e.) values
30mWcrr2
Before illumination 10 90.5 + 8.1 188 9.0 2.9 28 36
Within 1 min 186 1.7 1.1 76 9.1
(P= 0.002) (P= 0.002) (P= 0.004) (P= 0.004)
20-50 J cm-2 191 14.6 7.4 8.4 61
(20-26 min) (P= 0.7) (P= 0.4) (P= 0.3) (P= 0.02)
75 mW cm-2
Before illumination 8 103.6 ± 7.2 123 8.3 3.9 22 38
Within 1 min 112 0.9 0.7 91 1.8
(P= 0.008) (P= 0.02) (P= 0.02) (P= 0.02)
20-50 J cm-2 94 4.0 2.8 37 18
(6-10 min) (P= 0.02) (P= 0.1) (P= 0.4) (P= 0.03)
150 mWcm-2
Before illumination 10 92.9 ± 8.9 127 10.3 5.2 17 53
Within 1 min 129 1.7 0.7 73 7
(P= 0.002) (P= 0.002) (P= 0.004) (P= 0.002)
20-50 J cm-2 165 2.1 1.7 61 8.5
(2-6 min) (P = 0.002) (P = 0.004) (P= 0.01) (P= 0.002)
aTumourP02 was measured in three groups of animals, one for each fluence rate; changes inP02 were recorded for individual tumours from pre-illumination
through illumination as described; data were calculated from the pooled results of all measurements for each condition; P-values were calculated for differences
between the pre-illumination values and values of a given illumination condition using a paired test comparing changes within individual tumours.
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Figure 2 Histograms of tumourP02 measurements taken in tumours during
and after Photofrin PDT at 150 mW cm-2. Data were pooled from six (N)
individual tumours/animals; the number of recorded values for each condition
is indicated by n. (A) Within the first minute of illumination. (B) Within 1 min
after a 1-min illumination
hydrochloric acid (NEN Life Science Products, Boston, MA, USA)
was diluted in HBSS to 125 jiCi ml-'. Mice were anaesthetized as
described forpO2 measurements and injected with 0.2 ml (25 jiCi)
of 86RbCl intraorbitally. This injection route yielded identical
results to i.v. injection via tail vein (data not shown) and was
adopted for ease and accuracy. Two minutes later, mice were sacri-
ficed by cervical dislocation and their treated or untreated tumour
and skin patch were excised and weighed. Activity was counted
in a gamma counter (Cobra II Auto-Gamma Counter, Packard
Instrument, Meriden, CT, USA). For tumour tissue the percentage
of injected 86Rb taken up per g of tissue was used to express the
data, with values corrected for mouse body weight. Because ofthe
time-dependent development of oedema in the treated skin, and
thus increase in the weight ofthe excised skin, weight was not used
in the expression ofthe skin results. Instead, care was taken to keep
the diameter of the excised skin patch as identical as possible.
Values were only corrected for mouse body weight.
Tumour and skin perfusion was determined during PDT at 30
and 150 mW cm-2 by injecting 86Rb after 1 min of light exposure
and continuing with a further 2 min oflight exposure before sacri-
ficing the animal. Perfusion was also assessed immediately and
1, 5 and 24 h after PDT of 100 J cm-2 at fluence rates of 30 and
150 mW cm-2. Appropriate light-only and drug-only controls were
included. At least three animals were used for each experimental
condition.
Computer simulation of 302 and 102 distribution
during PDT
Computer software (PDT molecular oxygen-depletion model, PDT
MODeM), developed by Henning et al (1995) based on previous
mathematical modelling by Foster et al (1991), was used to visu-
alize the effects of fluence rate on tumour 3°2 and 102 distribution
throughout the intercapillary space during PDT and to predict a low
fluence rate that might allow sustained tumour oxygenation in the
RIF tumour model. In addition to the Photofrin-specific photophys-
ical and photochemical reaction parameters (Foster et al, 1991), the
following RIF tumour-specific parameters were entered: Photofrin
tumour concentration, 11.2 jg g-' (experimentally determined as
described above); vessel diameter, 7.55 jm (Fenton and Way,
1993); intercapillary distance, 240jm (Fenton and Way, 1993);
intracapillary HbO2 saturation, 30% (Rofstad et al, 1988).
Statistical considerations
For oxygen measurements, mean and median pO2 values were
calculated using the programpO2 Pool (version 1.2), provided by
Table 2 Tumour PO2 after Photofrin PDTa
Treatment Time No. No. of Mean tumour Mean Median % of % of
conditions after of values volume P02 PO2 values values
PDT (h) mice (mm3 ± s.e.) (mmHg) (mmHg) < 2 mmHg .5 mmHg
Photofrin NA 32 481 95.0 ± 4.50 10.2 4.0 21 44
control
30 mWcm-2, 0.1 5 151 80.0±11.1 9.0 4.1 22 44
100 J cm-2 1 6 166 75.8 ± 13.3 3.9 1.1 66b 21
3 5 163 87.0± 13.1 1.1b 1.0 85b 0
5 5 152 86.3 ± 2.60 2.1 1.3 70b 9b
150 mW cm-2, 0.1 5 100 89.9±14.6 11.4 6.0 9.0 54
100Jcm-2 1 5 134 85.5±19.3 2.9 1.8 54b 16
3 5 126 90.3±11.4 2.1b 1.5 57b 7.9b
5 5 104 86.5 ± 12.9 2.0b 1.5 63b 5.8b
aTumourP02 was measured in separate groups of animals for each condition and time interval between PDT andP02 measurement. bStatistically different (P<
0.05 by unpaired t-test) from Photofrin controls.
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Eppendorf. Percentages of values < 2 mmHg and . 5 mmHg were
determined manually. The data were imported into Origin
(Microcal TM Software, Northampton, MA, USA) and pO2
histograms (i.e. pO2 frequency distribution) were drawn with a
class width of 2 mmHg. The Wilcoxon test was used for paired
analysis of pO2 data from experimental groups, in which each
tumour served as its own control. The unpaired Student's t-test
was used for comparisons of pO2 data between experimental
groups, as well as for analysis of perfusion results. P-values of
<0.05 were considered to be significant. The Cox-Mantel test
(Mantel, 1966) was performed in BMDP IL (1990) for analysis of
time oftumour regrowth after treatment. All analyses were carried
out using Instat (GraphPad Software, San Diego, CA, USA),
unless otherwise indicated.
RESULTS
Simulated distribution of 302 and 102 during PDT
To facilitate the choice of appropriate experimental conditions for
the biological end points, the effects of fluence rate on the distribu-
tion of 3°2 and '02 throughout the intercapillary space were
computer simulated. Figure IA depicts the predicted steady-state
distribution in 3°2 concentration in the RIF tumour during
Photofrin PDT as a function of distance from a capillary during
tumour illumination at 30, 75 or 150 mW cm-2. These steady-state
values were reached within seconds of beginning illumination.
According to Figure IA, the radius ofwell-oxygenated cells around
the capillary can be expected to decrease with increasing fluence
rate. Correspondingly, the radius of cells exposed to high levels of
102 can also be expected to shrink (Figure iB). It is noteworthy,
however, that at high fluence rates the peak 102 concentrations in
close proximity to the vessel will greatly exceed those at low
fluence rates. As the model predicted that the fluence rate of
30 mW cm-2 would allow relatively sustained tumour oxygenation
during PDT, the fluence rate of 30 mW cm-2 was chosen for our
experimental studies. Fluence rates of 150 mW cm-2, the most often
used clinical fluence rate, and 75 mW cm-2 were chosen because
the model predicted marked, graded tumour oxygen depletion.
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Figure 3 Kaplan-Meier plots of tumour regrowth after Photofrin PDT at
different fluence rates. The percentage of tumours not having reached a
volume of 400mm3 is plotted against time after PDT; the hanging points
represent those tumours cured at 90 days (2160 h) after treatment. (*)
Controls received Photofrin only; the other groups received PDT with
Photofrin and 100 J cm-2 of light at 30 mW cm-2 (A), 75mW cm-2 (0) or
150 mW cm-2 (O). PDT-treated groups contained a minimum of 11 animals,
the Photofrin controls contained four
Tumour P02 during PDT
To test the relevance of the above predictions, direct measure-
ments of intratumour oxygen partial pressures were carried out
before and during Photofrin PDT. A number ofcontrol conditions
were initially evaluated to determine the reliability ofthe method.
No significant differences (all P-values 2 0.83) were detected
between measurements in separate groups of untreated animals
with or without anaesthesia (no anaesthesia: mean 11.4 mmHg,
median 4.1 mmHg, < 2 mmHg 37%, 2 5 mmHg 44%, N = 9;
anaesthesia: mean 11.5 mmHg, median 4.7 mmHg, < 2 mmHg
33%, .5 mmHg 50%, N= 18). Therefore all subsequent measure-
ments were carried out in anaesthetized animals. Light-only (no
Photofrin) effects were evaluated sequentially in individual
tumours (N = 9). No significant difference (P 2 0.22) was found
between measurements before illumination (mean 8.3 mmHg,
median 2.7 mmHg, <2 mmHg 34%, .5 mmHg 34%), those
within the first minute of illumination (mean 8.5 mmHg, median
2.8 mmHg, < 2 mmHg 49%, 2 5 mmHg 43%) and those during
the delivery of
- 20-50 J cm-2 at 150 mW cm-2 (mean 10.1 mmHg,
median 2.4 mmHg, < 2 mmHg 46%, .5 mmHg 41%). The
number of previous tracks used within the limits of our experi-
mental set-up did not seem to influence subsequent measurements
within a given tumour. Effects of photosensitizer alone (no
tumour illumination) were analysed through comparisons of
tumour pO2 in mice receiving Photofrin (mean 10.2 mmHg,
median 4.0 mmHg, < 2mmHg 21%, 2 5 mmHg 44%, N = 32)
with those who received nothing but anaesthesia (see above).
No significant differences were found between these two groups
(P 2 0.08). While, overall, the above control groups were quite
consistent, variations in measurements among individual tumours
were found. This appeared to be related to tumour geometry,
with more compact, nodular tumours exhibiting lower intratu-
mour pO2 than flat and thin tumours of similar volume. For this
reason, fluence rate experiments were carried out with each
animal/tumour serving as its own control, and data were evaluated
in a paired manner.
Table 1 summarizes the effects of illumination at different
fluence rates on tumour oxygen pressure in Photofrin-sensitized
tumours. When pO2 was measured within the first minute of light
exposure, all three fluence rates produced similar, significant
decreases in mean and median pO2 values, as well as in the
percentage of values 2 5 mmHg, with a concomitant increase in
values < 2 mmHg. When pO2 was measured again in the same
tumours under illumination after an approximate fluence of
20-50 J cm-2 had been accumulated, the 30 mW cm-2 fluence rate
emerged as markedly different from the higher fluence rates; all
oxygenation parameters had returned and slightly surpassed the
initial baseline values, with the percentage of values .5 mmHg
actually being significantly greater than baseline. A smaller
recovery was found with the 75 mW cm-2 fluence rate and no
recovery at all with the 150mWcm-2 fluence rate.
The reversibility of fluence rate-dependent oxygen depletion
was tested in an additional group of animals. Figure 2 represents
histograms derived from measurements in Photofrin-sensitized
tumours under 150 mW cm-2 illumination, taken within the first
minute of light (Figure 2A) and again within 1 min after termina-
tion of light (Figure 2 B). Severe oxygen depletion under high
fluence rate exposure was again seen. However, oxygenation was
rapidly restored to levels similar to those before illumination (see
Table 1) when illumination had ceased.
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Figure 4 Assessment of changes in the microvascular perfusion of RIF
tumours after Photofrin PDT as determined by 86RbCI uptake. Tumours
treated with 100 J cm-2 at 30 (A) and 150 mW cm-2 (0). Controls (0) include
untreated tumours and tumours receiving light only at 30 and 150 mW cm-2,
100 J cm-2. Each point is the mean ± s.e. from at least three animals
Analysis of the pooled results of tumour temperature measure-
ments showed no consistent changes at any fluence rate, and no
significant differences between pre-illumination conditions could
be demonstrated by paired analysis ofvalues. However, changes in
temperature in individual tumours ranged widely, and both
temperature increases and decreases were registered. Light of
150 mW cm-2 for 2 min, for example, resulted in average tempera-
ture changes from - -20C to - + 20C.
Tumour P02 after PDT
In a separate series ofexperiments, tumourpO2 was measured in a
time-dependent manner after completion of light treatment
(fluence 100 J cm-2) at 30 and 150 mW cm-2, with different groups
of animals used for each measurement condition (Table 2). No
significant differences from untreated controls were found in any
ofthe oxygenation parameters immediately after cessation oflight
at either fluence rate. With time, values for mean and medianpO2
and the percentage of values 2 5 mmHg decreased, while the
percentage of values < 2 mmHg increased. Differences in the
percentage ofvalues < 2 mmHg and 2 5 mmHg were both signifi-
cantly different from controls by 3 h post treatment, but not
significantly different between the two fluence rates.
Tumour response to PDT
The possible treatment advantage to maintaining tumour pO2 by
lowering the PDT fluence rate was examined through tumour-
response studies (Figure 3). In animals thatreceived a total fluence
of lOOJ cm-2, the time of tumour regrowth to a volume of
400 mm3 was clearly fluence rate dependent, with the most rapid
regrowth after the 150 mW cm-2 treatments and the most
pronounced regrowth delay after 30 mW cm-2 PDT. Analysis of
the median time of tumour regrowth to 400 mm3 showed the
differences at these two fluence rates to be significant
(P = 0.0004). Furthermore, while the 150 mW cm-2 fluence rate
did not cure (O out of 14 animals) any of the mice treated with
100 J cm-2, cures were found at the lower fluence rates: 9% (1 out
of 11 animals) at 75 mW cm-2 and 15% (2 out of 13 animals) at
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Figure 5 Assessment of changes in the microvascular perfusion in the
normal back skin of mice after Photofrin PDT. Skin treated with 100 mW cm-2
at 30 (A), 75 (0) and 150 mW cm-2 (0). Each point is the mean ± s.e. from
at least three animals. (A) Perfusion determined using the fluorescein dye
exclusion assay. Data represent the fluorescein fluorescence ratios of
treated/untreated skin. (B) Perfusion determined by 86RbCI uptake. Data at
-1 h represent light-only controls
30 mW cm-2. Even when a higher fluence was used (135 J cm-2),
no cures (none out of eight animals) were found with 150 mW
cm-2, while with 30 mW cm-2 cures (two out of eight animals)
were still found at a fluence of75 J cm-2.
Microvascular perfusion during and after PDT
In view of the predicated differences in peak 102 generation near
the vessels as a function of fluence rate (Figure 1B), fluence rate-
dependent changes in tumour and skin microvascular perfusion
were examined.
The attempts to detect tumour perfusion changes during PDT
light exposure (at 1 min of light at either 30 or 150 mW cm-2)
did not reveal any statistically significant differences from control
tumours [untreated controls, 53.6 ± 11.2 (% of injected/g tissue x
body weight); light only, 30 mW cm-2, 36.0 ± 7.6; PDT,
30 mW cm-2, 46.8 ± 5.6; light only, 150 mW cm-2, 54.1 ± 6.2;
PDT, 150 mW cm-2, 59.0 ± 4.6].
After PDT (100 J cm-2) vascular perfusion in the tumour, as
measured by 86Rb uptake, rapidly and markedly decreased with no
significant differences between fluence rates (Figure 4). Perfusion
remained low for at least 24 h, possibly showing a slight upward
trend at that time point. Perfusion changes in the normal cutaneous
microvasculature displayed a very different pattern. It has to be
noted that the development of cutaneous oedema with time after
PDT posed a problem for the usual presentation ofthe 86Rb uptake
assay data, as the increase in skin weight artificially depressed the
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measured values ofthe latertimepoints when these were corrected
for tissue weight. Tissue weight was therefore eliminated from the
data calculation and care was taken to excise and evaluate identi-
cally sized skin samples (Figure SB). As further validation of the
86Rb data, the fluorescein exclusion assay was also used to assess
cutaneous perfusion changes (Figure SA). Both approaches
yielded similar results that demonstrated significant differences in
the cutaneous vascular response to PDT as a function of fluence
rate. Light delivery of 100 J cm-2 at 150 mW cm-2 showed a -50%
reduction in perfusion by the end oflight exposure, but perfusion
returned to control levels within 1 h and remained there for the
24-h observation period. In contrast, the same fluence delivered
at 30 mW cm-2 produced no acute reduction in perfusion, but
perfusion decreased to very low levels over a 5-h post-PDT
interval. At 24 h, skin appeared virtually unperfused in the
fluorescein exclusion assay, but showed a slight recovery with the
86Rb assay. A fluence rate of 75 mW cm-2 (Figure SA) produced
intermediate results.
DISCUSSION
This study confirms the concept of photochemical oxygen deple-
tion during PDT, which was put forward by Tromberg et al (1990)
and Foster et al (1991), and provides direct experimental evidence
of PDT-induced oxygenation changes in a preclinical tumour
system.
Ourpre-light measurements ofRIFpO2 (median 2.9-5.2 mmHg)
agree well with studies by others (medians - 1.2-4.0 mmHg)
(Horsman et al, 1994; Honess et al, 1995; Kavanaugh et al, 1996)
using the Eppendorf oxygen electrode system. These values were
not significantly affected by the use ofsodium pentobarbital anaes-
thesia either in this study or in others (Kavanaugh et al, 1996).
Measurements of tumour pO2 during PDT at various fluence
rates (Table 1) revealed that lowerfluence rate was associated with
better sustained tumour oxygenation, in agreement with Foster's
modelling offluence rate-dependent photochemical oxygen deple-
tion (Foster et al, 1991). The enhanced tumour pO2 during lower
fluence rate PDT was also in overall agreement with the predic-
tions ofthe PDTMODeM computer simulation. This program was
developed as a research tool and is based on the simplest assump-
tions of oxygen demand and supply (Henning et al, 1995), i.e. it
does not consider such potential complications as changes in
fluence rate as light penetrates through tissue, photobleaching of
the sensitizer, uneven photosensitizer distribution, changes in
metabolic oxygen consumption and changes in vascular supply
during PDT. Accordingly, this program was used simply as aguide
to suggest fluence rates that would differentially affect tumourpO2
during PDT. The EppendorfpO2 histograph was used to directly
measure tumourpO2 during illumination at these fluence rates.
Close examination ofthe EppendorfpO2 measurements reveals
that while low PDT fluence rate enhanced tumour oxygenation
when a total fluence of20-50 J cm-2had been delivered, with only
1 min ofillumination all fluence rates resulted in a similar signifi-
cantdecrease in tumourpO2. Several explanations fortheseresults
are possible. (1) The absence of any significant difference in the
uniformly low pO2 values of the earliest measurements for the
three fluence rates may be a consequence ofthe limited sensitivity
ofthepO2 histograph at very low tissue oxygen tensions (Stone et
al, 1993). (2) The observed decreases in tumourpO2 during PDT
may be the result of vessel constriction and therefore reduced
blood flow, whereby low fluence rate would cause reversible
effects and high fluence rate would cause irreversible effects.
However, our own data on tumour perfusion do not show any
evidence of vessel constriction during light exposure, and several
other facts contradict this possibility. Studies by Fingar et al
(1992b) have found no acute vessel constriction associated with
the low dose (5 mg kg-') of Photofrin used in this study.
Additionally, we found that, after 150 mW cm-2 PDT, tumourpO2
recovered within 1 min of terminating illumination (Figure 2).
This observation is consistent with the concept of photochemical
oxygen depletion and observations by Tromberg et al (1990), and
does not agree with the finding by Fingar et al (1992b) of PDT-
induced vascular constriction lasting for -1 h after treatment. (3)
The observed recovery of tumour pO2 at low fluence rate with
low-treatment fluence may be due to a decrease in metabolic
oxygen consumption as a result of direct cell effects during PDT
(Gibson et al, 1990), i.e. the sustained oxygenation during low-
fluence-rate PDT would increase direct cell damage and thus
decrease metabolic oxygen consumption. However, Foster et al
(1991) have described any such decrease as negligible compared
with photochemical oxygen depletion during PDT, thus this is an
unlikely mechanism. (4) The fluence rate-dependent recovery of
tumour oxygenation at lower fluence rates may be a consequence
of photosensitizer photobleaching. Such a mechanism has been
proposed by Foster and Nichols (1995) and Georgakoudi et al
(1997), who have mathematically modelled and experimentally
described the effects ofphotobleaching on the oxygen distribution
in multicellular spheroids. According to this concept, the photo-
sensitizer itself is destroyed via a self-sensitized singlet oxygen
reaction with the photosensitizer ground state during illumination
in the presence of molecular oxygen. This in turn decreases
successive photochemical oxygen depletion and extends the radius
of oxygen distribution within the tissue. The extreme, acute
oxygen depletion during high-fluence-rate PDT would limit
photobleaching, thus no recovery of tumour oxygenation would
occur. The impact of fluence rate on photosensitizer photo-
bleaching in vivo is currently under investigation.
Although the fluence rate of treatment did influence tumour
oxygenation during PDT, it did not affect tumourpO2 status after
PDT. At both high and low fluence rates tumour pO2 dropped
steadily with time after treatment (Table 2), consistent with our
earlierreports ofincreasing tumourhypoxia afterPDT (Henderson
and Fingar, 1987) and studies by others (Roberts et al, 1994; Chen
et al, 1996).
Consistent with the above observations, no differences were
found in tumour perfusion after high- or low-fluence-rate PDT. In
both cases, tumour perfusion progressively decreased with time
aftertreatment as has beendescribed by others (Roberts et al, 1994;
van Geel et al, 1994, 1996). However, marked differences were
found in cutaneous perfusion. The diverse effects on tumour and
normal vasculature may be related to differences in vascular archi-
tecture, allowing normal and tumour vessels to respond differently
to physical and chemical stimuli (Vaupel et al, 1989). Also, photo-
sensitizer distribution in and around normal and tumour vessels
may be different, therefore influencing local oxygen depletion
during PDT and consequently vascular responses.
Despite similar post-PDT hypoxia, low-PDT fluence rate did
enhance tumoricidal effects (Figure 3), as has been observed by
others notonly forPhotofrin but also forotherphotosensitizers such
as ALA-induced protoporphyrin IX, benzoporphyrin derivative
(BPD) and tetra (m-hydroxyphenyl) chlorin (mTHPC) (Gibson et
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al, 1990; linuma et al, 1995; Blant et al, 1996). In the present study
not only was the 30 mW cm-2 fluence rate superior to the higher
fluence rates at equal total fluence (100 J cm-2), but even lower
fluences produced more lasting tumour responses, implying
markedly enhanced PDT efficiency.
At least two mechanisms may be responsible for the fluence
rate-dependent differences in anti-tumour activity. First, the
increased oxygen availability throughout the tumour tissue during
illumination at low fluence rate seems to lead to a modest, but
statistically significant increase in direct photodynamic tumour
cell kill in this tumour model (Sitnik and Henderson, 1997).
Similarly, increased fluence rate-dependent cytotoxicity was
reported by Foster et al (1993) for multi-cell tumour spheroids in
vitro. Second, the severe disruption ofthe microvascular perfusion
of the tumour-surrounding skin at low-fluence-rate treatment may
delay the re-supply of oxygen and nutrition to any PDT-surviving
tumour cells and so retard tumour regrowth.
The observations reported here may be of significant clinical
importance if it can be shown that lower fluence rate does not
adversely affect therapeutic ratio. Preclinical studies examining
the influence of fluence rate on PDT exposure of normal tissue,
especially the skin, are currently underway, as is an extensive
clinical study determining tumour pO2 during PDT in patients
undergoing treatment ofneoplastic skin lesions.
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